07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335)

Endocrine/metabolic disease INDICATION: Diabetes Mouse studies suggest inhibiting NKP46 could help treat Type I diabetes. In mice, an antibody against mouse NKP46 decreased expression of the protein on NK cells - which are involved in β cell...
07:00 , Apr 9, 2015 |  BC Innovations  |  Translation in Brief

Blocking β cell destruction

Most attempts to develop therapies for Type I diabetes focus on regenerating pancreatic β cells or restoring their function. A group of researchers in Israel has developed a different approach by finding an antibody that...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

BioLineRx, JHL Biotech preclinical data

In a mouse model of diabetes, short-term treatment with BL-9020 significantly reduced the incidence of developing Type I diabetes, led to significantly less severe hyperglycemia and significantly reduced body weight vs. saline-treated controls (p<0.05 for...
07:00 , Mar 10, 2014 |  BioCentury  |  Emerging Company Profile

JHL: Biomanufacturing solar system

JHL Biotech Inc. aims to build a network of R&D and manufacturing facilities across Asia to develop, manufacture and commercialize affordable, high-quality biologics that meet international standards. The company is developing an internal pipeline of...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

BioLineRx, JHL Biotech deal

BioLineRx granted JHL exclusive rights to develop and commercialize BL-9020 in China and Southeast Asia as well as worldwide manufacturing rights. BioLineRx retains development and commercialization rights in the rest of the world. Each...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

BioLineRx, Ben-Gurion University, Hadassah University Hospitals, The Hebrew University of Jerusalem deal

The technology transfer arms of the universities granted BioLineRx exclusive, worldwide rights to BL-9020, a mAb inhibitor of natural cytotoxicity triggering receptor 1 ( NCR1; NKP46; CD335), to treat Type I...